## **EISAI CO LTD**

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock



## **Company Profile**

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

## Financial figures, Fiscal year: from 01.04. to 31.03. 2022 2024 2023 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 722.237.000.000 621.847.000.000 640.260.000.000 Common stock capital 44,986,000,000 44,986,000,000 44,986,000,000 **Fixed assets** 671,562,000,000 641,503,000,000 599,055,000,000 Equity capital of a company 898,975,000,000 822,571,000,000 771,533,000,000 304,678,000,000 267,350,000,000 309,633,000,000 Cash and cash equivalents **Accrued liabilities** 1.413.000.000 1.299.000.000 1.473.000.000 Other assets **Current liabilities** 304,472,000,000 298.945.000.000 313,333,000,000 Prepayments and accrued income Non-current liabilities 190,353,000,000 141,834,000,000 154,448,000,000 Different income Other liabilities 19,096,000,000 19,407,000,000 15.730.000.000 1,263,350,000,000 1.239.315.000.000 **Total assets** 1 393 799 000 000 1 393 799 000 000 1,263,350,000,000 1,239,315,000,000

	2024	2023	2022
Accounting standard	IFRS	IFRS	IFRS
Employees	11,067	11,076	11,322
Equity ratio	66.17%	66.90%	64.09%
Debt-equity ratio	51.12%	49.48%	56.04%

2024

29.18%

2023

-26.27%

**Tax Expense Rate** 

2022

16.05%

## **EISAI CO LTD**

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock

Income statement			
	2024	2023	2022
Turnover	741,751,000,000	744,402,000,000	756,226,000,000
Net income	42,407,000,000	55,432,000,000	47,954,000,000
EBIT	324,198,000	255,930,000	326,802,000
Operating income before taxes	61,823,000,000	45,012,000,000	54,458,000,000
Cash Flow	55,993,000,000	-1,772,000,000	117,590,000,000
Net interest income	7,790,000,000	2,357,000,000	-9,000,000
Research and development expenses	153,092,000,000	156,691,000,000	158,030,000,000
Income taxes	18,040,000,000	-11,824,000,000	8,741,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	402,142	403,251	400,756

Board of Directors		
Clive Thornley	Member of Supervisory Board	
Fumihiko Ike	Member of Supervisory Board	
Hiroyuki Kato	Member of Supervisory Board	
Kenta Takahashi	Member of Supervisory Board	
Ryota Miura	Member of Supervisory Board	
Takuji Kanai	Member of Supervisory Board	
Toru Moriyama	Member of Supervisory Board	
Yoshiteru Kato	Member of Supervisory Board	
Yuko Yasuda	Member of Supervisory Board	
Yumiko Miwa	Member of Supervisory Board	

Members of Management Board			
Haruo Naito	Chairman of Managing Board		
Akiko Nakahama	Member of Executive Committee		
Gary Hendler	Member of Executive Committee		
Ivan Cheung	Member of Executive Committee		
Kazuhiko Tamura	Member of Executive Committee		
Keisuke Naito	Member of Executive Committee		
Kenta Takahashi	Member of Executive Committee		
Lynn Kramer	Member of Executive Committee		
Masatomi Akana	Member of Executive Committee		
Mitsuo Kosaka	Member of Executive Committee		
Mitsuru Shomon	Member of Executive Committee		
Sayoko Sasaki	Member of Executive Committee		
Shin Ujiie	Member of Executive Committee		
Shohei Kanazawa	Member of Executive Committee		
Takashi Owa	Member of Executive Committee		
Tatsuyuki Yasuno	Member of Executive Committee		
Terushige like	Member of Executive Committee		
Teruyuki Masaka	Member of Executive Committee		
Toshitaka Asano	Member of Executive Committee		
Yanhui Feng	Member of Executive Committee		
Yasushi Okada	Member of Executive Committee		